- Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc (NYSE:MRK).
- The platform, also utilized in the vaccine candidate’s Phase 2b study, will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
- In January, Personalis approved a reduction in its workforce by up to approximately 30% to reduce operating costs and improve operating efficiency.
- The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023.
- Price Action: PSNL shares are up 26.80% at $3.86 on the last check Friday.
On Thursday April 25, 2024, Atlassian Reported Q4 Revenue Guidance Of $1.12B-$1.135B Vs $1.11B Est.; Expected Cloud Revenue Growth YoY Is ~32%; Expected Data Center Revenue Growth YoY In The Range Of 40%-42%
Financial Targets:Atlassian is providing its financial targets as follows:Fourth Quarter Fiscal Year 2024:Total revenue is expected to be in the range of $1,120 million to $1,135 million.Cloud revenue growth
